RenovoRx Inc
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was… Read more
RenovoRx Inc (RNXT) - Total Liabilities
Latest total liabilities as of September 2025: $3.13 Million USD
Based on the latest financial reports, RenovoRx Inc (RNXT) has total liabilities worth $3.13 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
RenovoRx Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how RenovoRx Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
RenovoRx Inc Competitors by Total Liabilities
The table below lists competitors of RenovoRx Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Li Cheng Enterprise Co Ltd
TW:4426
|
Taiwan | NT$2.34 Billion |
|
Volt Lithium Corp.
OTCQB:VLTLF
|
USA | $4.13 Million |
|
Zedge Inc
NYSE MKT:ZDGE
|
USA | $9.75 Million |
|
PGG Wrightson Limited
PINK:PGWFF
|
USA | $312.90 Million |
|
Enterprise Diversified Inc
OTCQB:ENDI
|
USA | $19.37 Million |
|
Hipages Group Holdings Ltd
AU:HPG
|
Australia | AU$24.56 Million |
|
Denge Yatirim Holding AS
IS:DENGE
|
Turkey | TL490.50 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down RenovoRx Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 5.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how RenovoRx Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for RenovoRx Inc (2019–2024)
The table below shows the annual total liabilities of RenovoRx Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.64 Million | -18.50% |
| 2023-12-31 | $4.47 Million | +305.26% |
| 2022-12-31 | $1.10 Million | +17.48% |
| 2021-12-31 | $938.00K | -94.34% |
| 2020-12-31 | $16.57 Million | +1958.39% |
| 2019-12-31 | $805.00K | -- |